Aldeyra Therapeutics Statistics
Total Valuation
ALDX has a market cap or net worth of $94.49 million. The enterprise value is $40.58 million.
Important Dates
The next estimated earnings date is Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ALDX has 60.18 million shares outstanding. The number of shares has increased by 0.96% in one year.
| Current Share Class | 60.18M |
| Shares Outstanding | 60.18M |
| Shares Change (YoY) | +0.96% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 3.26% |
| Owned by Institutions (%) | 53.21% |
| Float | 48.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.15 |
| P/TBV Ratio | 2.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.58, with a Debt / Equity ratio of 0.35.
| Current Ratio | 2.58 |
| Quick Ratio | 2.52 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -18.51 |
Financial Efficiency
Return on equity (ROE) is -58.73% and return on invested capital (ROIC) is -30.17%.
| Return on Equity (ROE) | -58.73% |
| Return on Assets (ROA) | -24.95% |
| Return on Invested Capital (ROIC) | -30.17% |
| Return on Capital Employed (ROCE) | -79.69% |
| Weighted Average Cost of Capital (WACC) | 11.30% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.23M |
| Employee Count | 8 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -40.60% in the last 52 weeks. The beta is 1.33, so ALDX's price volatility has been higher than the market average.
| Beta (5Y) | 1.33 |
| 52-Week Price Change | -40.60% |
| 50-Day Moving Average | 3.03 |
| 200-Day Moving Average | 4.63 |
| Relative Strength Index (RSI) | 31.99 |
| Average Volume (20 Days) | 1,725,776 |
Short Selling Information
The latest short interest is 5.54 million, so 9.21% of the outstanding shares have been sold short.
| Short Interest | 5.54M |
| Short Previous Month | 5.49M |
| Short % of Shares Out | 9.21% |
| Short % of Float | 11.42% |
| Short Ratio (days to cover) | 0.84 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -35.27M |
| Pretax Income | -33.85M |
| Net Income | -33.85M |
| EBITDA | -35.01M |
| EBIT | -35.27M |
| Earnings Per Share (EPS) | -$0.56 |
Full Income Statement Balance Sheet
The company has $70.04 million in cash and $15.53 million in debt, giving a net cash position of $54.51 million or $0.91 per share.
| Cash & Cash Equivalents | 70.04M |
| Total Debt | 15.53M |
| Net Cash | 54.51M |
| Net Cash Per Share | $0.91 |
| Equity (Book Value) | 44.25M |
| Book Value Per Share | 0.74 |
| Working Capital | 43.97M |
Full Balance Sheet Cash Flow
| Operating Cash Flow | -33.35M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 251,993 |
| Net Borrowing | n/a |
| Free Cash Flow | -33.35M |
| FCF Per Share | -$0.55 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |